Two-year results of intravitreal triamcinolone acetonide injection for the treatment of diabetic macular edema

被引：20

作者：

Batıoğlu F. ^{[1
,2
]}

Özmert E. ^{[1
]}

Parmak N. ^{[1
]}

Çelik S. ^{[1
]}

机构：

[1] Department of Ophthalmology, Faculty of Medicine, Ankara University, Ankara 06100, Mamak Street

[2] Ankara

来源：

International Ophthalmology | 2007年 / 27卷 / 5期

关键词：

Diabetic macular edema; Intravitreal triamcinolone acetonide; Optical coherence tomography;

D O I：

10.1007/s10792-007-9072-7

中图分类号：

学科分类号：

摘要：

Purpose: To investigate 2-year results of intravitreal triamcinolone acetonide injection for the treatment of diffuse diabetic macular edema unresponsive to previous laser photocoagulation. Method: The study included 75 eyes of 75 diabetic patients with clinically significant diffuse macular edema that had failed to respond to previous laser photocoagulation. An intravitreal injection of triamcinolone acetonide at the dose of 4 mg/0.1 ml was administered. Best-corrected visual acuity was measured as the logarithm of the minimum angle of resolution (logMAR), and central macular thickness was obtained by optical coherence tomography at each visit. Intraocular pressure and lenticular status were also evaluated. Differences among measurements were evaluated by Friedman two-way analysis of variance by ranks. Mean follow-up period was 24.7 ± 5.9 months. Results: The mean central macular thickness, which was obtained 3 days, 1 month, 3 months, 6 months, 9 months, 12 months, 18 months and 24 months postoperatively, was significantly different from the baseline measurement (P < 0.001). Mean best-corrected logMAR visual acuity improved significantly from baseline at the 1- month and 3-month follow-up intervals (P < 0.05), but there was no significant change at the 6- month, 9-month, 12-month, 18-month or 24-month follow-up periods (P > 0.05). During the follow-up, 29 (38.7%) eyes received re-injection of intravitreal triamcinolone. Twenty-one (28%) eyes developed intraocular pressure values higher than 21 mmHg, and 18 (24%) eyes developed cataract. Thirteen (17.3%) eyes required cataract and/or glaucoma surgery. Conclusions: In refractory diabetic macular edema, intravitreal triamcinolone effectively reduces foveal thickness and improves visual acuity in the short term, but with the extended follow-up, the number of recurrences and steroid-related complications were shown to increase. Nevertheless, it may be a therapeutic option in some patients that do not respond to previous laser photocoagulation. © Springer Science+Business Media, Inc. 2007.

引用

页码：299 / 306

页数：7

共 24 条

[1]

Ferris F.L., Patz A., Macular edema. A complication of diabetic retinopathy, Surv Ophthalmol, 28, pp. 452-461, (1984)

[2]

Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1, Arch Ophthalmol, 103, pp. 1796-1806, (1985)

[3]

Lee C.M., Olk R.J., Modified grid laser photocoagulation for diffuse diabetic macular edema: Long-term visual results, Ophthalmology, 98, pp. 1594-1602, (1991)

[4]

Martidis A., Duker J.S., Greenberg P.B., Et al., Intravitreal triamcinolone for refractory diabetic macular edema, Ophthalmology, 109, 5, pp. 920-927, (2002)

[5]

Ip M.S., Kumar K.S., Intravitreous triamcinolone acetonide as a treatment for macular edema from central retinal vein occlusion, Arch Ophthalmol, 120, pp. 1217-1219, (2002)

[6]

Antcliff R.J., Spalton D.J., Stanford M.R., Et al., Intravitreal triamcinolone for uveitic cystoid macular edema: An optical coherence tomography study, Ophthalmology, 108, pp. 765-772, (2001)

[7]

Benhamou B., Massin P., Haouchine B., Et al., Intravitreal triamcinolone for refractory pseudophakic macular edema, Am J Ophthalmol, 135, pp. 246-249, (2003)

[8]

Tano Y., Chandler D., Machemer R., Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide, Am J Ophthalmol, 90, pp. 810-816, (1980)

[9]

Danis R.P., Bingaman D.P., Yang Y., Ladd B., Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide, Ophthalmology, 103, pp. 2099-2104, (1996)

[10]

Danis R.P., Ciulla T.A., Pratt L.M., Anliker W., Intravitreal triamcinolone acetonide in exudative age-related macular degeneration, Retina, 20, pp. 244-250, (2000)

← 1 2 3 →